Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)

NCT01215175 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Infections

Interventions

BIOLOGICAL: Prevnar™
BIOLOGICAL: V114, Aluminum Adjuvanted
BIOLOGICAL: V114, Aluminum Nonadjuvanted

Sponsor

Merck Sharp & Dohme LLC